title: Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity.
abstract: METHODS
  Double-blind, randomised, multicentre study.
  
  
  OBJECTIVE
  Efficacy and tolerability of propiverine extended-release (ER) compared with immediate-release (IR) were evaluated in patients with proven neurogenic detrusor overactivity (NDO).
  
  
  METHODS
  Six Spinal Cord Injury Units located in Austria, Germany and Romania.
  
  
  METHODS
  Propiverine ER 45 mg s.i.d. or IR 15 mg t.i.d. were administered in patients with proven NDO. Outcomes were assessed at baseline (V1), and after 21 days of treatment (V2): Reflex volume served as primary, leak point volume and maximum detrusor pressure as secondary efficacy outcomes, treatment-related adverse events as tolerability outcomes.
  
  
  RESULTS
  Sixty-six patients with proven NDO were enrolled. Reflex volume (ml) increased significantly in the IR (V1: 100.9, V2: 202.9) and in the ER (V1: 89.8, V2: 180.3) group, no significant intergroup difference. Leak point volume increased, and maximum detrusor pressure decreased significantly in both groups, no significant intergroup differences. The percentage of patients presenting with incontinence was reduced by 14% in the IR and by 39% in the ER group, the difference is significant. Treatment-related adverse events manifested in 42 and 36% following propiverine IR and ER, respectively.
  
  
  CONCLUSIONS
  The urodynamic efficacy outcomes demonstrated both galenic formulations to be equieffective. However, following propiverine ER 45 mg s.i.d. higher continence rates compared with propiverine IR 15 mg t.i.d. were achieved, possibly indicative of more balanced plasma-levels. A slight tendency for superior tolerability outcomes of propiverine ER compared with IR was demonstrated.
authors: Department of Urology and Paediatric Urology, Universität Essen, Essen, Germany. manfred@stoehrer.com
authors: M
authors: M
authors: Stöhrer
authors: G
authors: G
authors: Mürtz
authors: G
authors: G
authors: Kramer
authors: W
authors: W
authors: Warnack
authors: G
authors: G
authors: Primus
authors: V
authors: V
authors: Jinga
authors: A
authors: A
authors: Manu-Marin
authors: N
authors: N
authors: Calomfirescu
authors: G
authors: G
authors: Strugala
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001561:Benzilates / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013119:Spinal Cord Injuries / Q000150:complications*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy* / Q000209:etiology; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics; D064804:Urological Agents / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D001561:Benzilates; D003692:Delayed-Action Preparations; D064804:Urological Agents; C015586:propiverine